Mouse Study Shows NMN Can Prevent Diabetic Kidney Disease

Researchers show that pre-emptive short-term NMN treatment increases the survival of diabetic mice with early stage kidney disease.

Up to 40% of patients with diabetes progress to the deterioration of kidney function (a condition called diabetic nephropathy), the leading cause of kidney (renal) failure. Progression of diabetic nephropathy has been shown to go hand in hand with metabolic abnormalities and the renal dysregulation of NAD+ — a cofactor that enzymes participating in a multitude of critical cell functions including healthspan and lifespan depend on for their function. Nicotinamide mononucleotide (NMN) is the precursor of NAD+, which, in several disease models, researchers have administered with favorable outcomes.

In an article published in the Journal of the American Society of Nephrology, Yasuda and colleagues from Keio University showed long-lasting protection against early diabetic nephropathy by short-term supplementation with NMN in mice. Specifically, two weeks of NMN injection treatment (500 mg/kg) decreased a condition called albuminuria — when kidney damage causes excess buildup of proteins in urine — and survival rates significantly increased. These improvements were accompanied by improvements in the health and form of the kidney’s substructures and specialized cells critical to its filtration function.

 

CH SIMPLIFIED
CH SIMPLIFIED